November 2019
The European Medicines Authority, Committee for Medicinal Products for Veterinary Use (CVMP) adopted by majority a positive opinion for an initial marketing authorisation application for STELFONTA®, from QBiotics Group Limited. This supports STELFONTA® (tigilanol tiglate) as an oncology veterinary product. Formal registration confirmation is expected early January.
October 2019
Dr Susan Foden joined the Board of QBiotics as a non-executive director on 14 October 2019.
October 2019
The Veterinary Cancer Society (VCS) Conference is the largest scientific meeting for veterinary oncology professionals globally. This year over 670 veterinary oncologists and associated health professionals attended the conference in Houston, USA. QBiotics' anticancer product tigilanol tiglate was the subject of two abstracts selected by the VCS scientific committee for presentation during the conference.
September 2019
Dr Chad Johannes DVM, Diplomate ACVIM (SAIM, Oncology) presented the tigilanol tiglate canine mast cell tumour (MCT) pivotal field efficacy clinical trial results at two recent prestigious international congresses
11 April 2019
The tigilanol tiglate canine dose characterisation study has been published as an original research article in the leading international journal, Frontiers in Veterinary Science.